Analisi di costo-utilità di ceftolozano/tazobactam rispetto a meropenem in pazienti con polmonite acquisita in ospedale (HABP) o polmonite associata a ventilazione meccanica (VABP)

OBJECTIVE: This study aims to evaluate the cost-effectiveness of ceftolozane/tazobactam compared to meropenem for the treatment of patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP) from the Italian National Health Service (NHS) and social perspective. METHOD:...

Descripción completa

Detalles Bibliográficos
Autores principales: Mennini, Francesco Saverio, Paoletti, Martina, Bini, Chiara, Marcellusi, Andrea, Falcone, Marco, Andreoni, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768596/
https://www.ncbi.nlm.nih.gov/pubmed/36628307
http://dx.doi.org/10.33393/grhta.2022.2287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768596/
https://www.ncbi.nlm.nih.gov/pubmed/36628307
http://dx.doi.org/10.33393/grhta.2022.2287

Ejemplares similares